Summary

The U.S. administration has threatened tariffs of up to 200% on imported generic drugs. Branded medicines have seen limited impact so far. In part, that is because 17 drugmakers signed “most favored nation” pricing deals in exchange for tariff relief. Generics are a different case. Their margins are thin. As a result, even small added costs can reshape supply and price. Therefore, this is not only a trade story. It is a market-access story.

Access Impact

Policy can move access risk overnight.

A tariff changes the cost of a medicine before it reaches a patient. For generics, that matters a lot. Manufacturers work on slim margins, so they cannot easily absorb new costs. As a result, some products could be discontinued. Others could face shortages. In some cases, cost-cutting could put product quality at risk. Consequently, the risk is not spread evenly. Instead, it depends on where a company makes its products and where it buys its ingredients. Specifically, a policy shock can change the value case for a product without any new clinical data. Moreover, the timing is hard to predict, which makes planning difficult.

Budget Impact and Resources

Tariffs act like a hidden cost increase. If levies hit finished products, importers pay more at the border. For a low-margin generic, that cost has to go somewhere. It can raise the price, cut the supply, or end the product. Notably, exposure differs sharply by company. Firms that rely on imported finished goods carry more risk. By contrast, firms with local production are better protected. For a payer or a health system, the budget effect is not abstract. It shows up as higher prices or missing products. Furthermore, a single tariff line can shift a whole procurement budget. As a result, health systems may face trade-offs they did not plan for.

Care-Pathway Integration

Shortages break care pathways. Generic drugs are the backbone of routine treatment. Many standard therapies depend on them. If a generic disappears, clinicians must switch patients to another option. That is not always simple. Sometimes there is no equal substitute. As a result, a supply shock can disrupt treatment far beyond a single product. Therefore, access risk here is about availability, not only price. Moreover, a disruption in one class can ripple across a whole treatment pathway. Specifically, hospital protocols are built around reliable supply. When that supply breaks, the cost of switching is real.

Residual Uncertainty and Equity

The details are not yet known. The real effect depends on the final policy design. If tariffs cover only finished products, some companies stay insulated. If they also cover ingredients, exposure widens. Even so, markets have already reacted. Shares of several generic makers fell when the threat became public. Furthermore, shortages tend to hit the most price-sensitive patients first. As a result, an equity gap can open between those who can find alternatives and those who cannot. Moreover, uncertainty itself carries a cost. Consequently, buyers and investors tend to price in the unknown, often at a discount.

Risk Signal

Policy is a risk factor. Treat it like one.

Tariffs, reference pricing, and “most favored nation” deals all change the access environment. These forces do not appear in a clinical trial. Yet they can decide whether a product stays on the market, and at what price. Internal forecasts often assume a stable policy backdrop. In practice, that assumption is fragile. Notably, the same logic applies to branded assets under pricing pressure. Therefore, a standardized signal helps by making that exposure visible and comparable across a portfolio. For an investor or portfolio owner, the question is direct. If a pricing or supply shock hits tomorrow, which assets are most exposed — and could you defend that judgment in front of a board?

#MarketAccess #HTA #MARArating #DrugPricing

Follow MARA Rating for independent, standardized market-access risk analysis.